Product Information
RIVAROXABAN 2.5 MG TABLET is a generic product labeled by Apotex Corp., priced at $0.6496 per EA under NDC 60505625606. Its NADAC has been published 65 times since Jul 9, 2025.
FDA first approved this application on May 2, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5 mg/1
Manufacturer
Apotex Corp.NDC
60505625606
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RIVAROXABANApproval Type
Generic (ANDA)
FDA Application
ANDA217810FDA Approved
5/2/2025
TE Code
AB
On Market Since
5/2/2025
Pharmacological Classes
Price Statistics
The NADAC for RIVAROXABAN 2.5 MG TABLET has been published 65 times since Jul 9, 2025, and over the history we have for it it has declined 85.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6496 per EA |
|---|---|
| All-time high | $4.6446 (Aug 13, 2025) |
| All-time low | $0.6496 (Sep 23, 2026) |
| 52-week high | $3.3910 |
| 52-week low | $0.6496 |
| Median price | $1.0757 |
| Average price | $1.8086 |
| Largest weekly change | -32.4% (Nov 19, 2025) |
| Weeks tracked | 65 |
| Tracking since | Jul 9, 2025 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Apotex Corp. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rivaroxaban market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Factor Xa Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIVAROXABAN 2.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RIVAROXABAN 2.5 MG TABLET, manufactured by Apotex Corp., is $0.6496 per EA (NDC 60505625606), effective Sep 30, 2026.
How has the price of RIVAROXABAN 2.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for RIVAROXABAN 2.5 MG TABLET has declined 85.8%. It has been tracked across 65 weekly CMS publications since Jul 9, 2025.
What are the highest and lowest recorded NADAC prices for RIVAROXABAN 2.5 MG TABLET?
Since Jul 9, 2025, the NADAC for RIVAROXABAN 2.5 MG TABLET has ranged from a low of $0.6496 (Sep 23, 2026) to a high of $4.6446 (Aug 13, 2025), with a median of $1.0757 per EA.
Are there cheaper alternatives to RIVAROXABAN 2.5 MG TABLET?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RIVAROXABAN 2.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures RIVAROXABAN 2.5 MG TABLET?
RIVAROXABAN 2.5 MG TABLET (NDC 60505625606) is labeled by Apotex Corp., and CMS classifies it as a generic product.